At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Multicenter, Controlled, Double-Blind Study Using Immunoprophylaxis in the Primary Prevention of Allergic Disease (ITN025AD)
In Brief
A Phase 2 clinical trial evaluating Oral mucosal immunoprophylaxis (OMIP) and Placebo for Asthma and Allergic Sensitization. Completed, enrolled 51 participants across 3 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine whether early childhood exposure to common allergens (substances that can trigger allergies and asthma) can prevent the development of asthma in children at high risk for developing the disease.
Study Details
Timeline
Interventions
OMIP consists of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL.
The placebo consists of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL.